Abstract 4111
Background
Molecular heterogeneity drives tumour evolution and resistance to therapies. Because of biopsy challenges in non-small cell lung cancer (NSCLC), few studies compared the molecular profile between primary tumour (PT) and metastasis (Met). Here, we compare somatic single-nucleotide variants (SNVs), tumour mutational burden (TMB) and expression profiles between PT and matched metachronous Met in NSCLC patients (pts).
Methods
DNA and RNA were extracted from 14 matched fresh-frozen samples and PBMCs from 7 pts treated at the Institut d’Oncologie Thoracique (Gustave Roussy, GR) between 2011 and 2015. GATK4 Mutect2 were used for SNV calling and TMB on whole exome sequencing. Salmon was used for expression counts from RNAseq; Z-scores were computed by comparing data to 158 other NSCLC RNAseq from GR molecular profiling trials; GSVA R package was use to assess single sample gene set enrichment score (ssGSEA).
Results
Median age was 67 yo (62-78); 4/7 metastases were biopsied after chemotherapy; histology was adenocarcinoma (6) or large cell carcinoma (1). The median number of SNVs unique to PT or Met was 50 (10-143) or 79 (36-324), respectively; it was 65 (0-110) for shared SNVs; 6/7 pts had known driver alterations (TP53, KRAS, PIK3CA) in both lesions; one Met acquired a pathogenic KRAS G35C mutation. Median TMB was 3.9 (0.3-4.3) in PT and 4.1 (2.2-8.4) in Met. Genes with top negative Z-scores (MRFAP1, EP400, RIOX1, DDX27) were shared between PT and Met in 6/7 pts; genes with top positive Z-score were unique. ssGSEA-enriched genesets were shared between PT and Met; top enriched hallmarks included Myc targets, Mitotic Spindle, DNA repair, oxidative phosphorylation and TGFb signaling.
Conclusions
Matched comparison of molecular profiles between PT and Met evidence shared and unique alterations; this informs on tumor evolution and may help guiding treatment choice.
Clinical trial identification
Editorial acknowledgement
AK: AK was funded by the DUERTECC Gustave Roussy program
LCD: LCD was funded by the INSERM ATIP-Avenir grant from SPV
Legal entity responsible for the study
Sophie Postel-Vinay.
Funding
Cancéropole d’Ile de France.
Disclosure
A Kawachi: Funded by the DUERTECC Gustave Roussy program. L. Colmet-Daage: Funded by the INSERM ATIP-Avenir grant from SPV. L. Verlingue: Honoraria (self): Adaptherapy; Research grant / Funding (self): Bristol-Myers Squibb. D. Planchard: Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Celgene; Honoraria (self): Eli Lilly; Honoraria (self): Merck; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): prIME Oncology; Honoraria (self): Peer CME; Honoraria (self): Roche; Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Boehringer Ingelheim ; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: prIME Oncology; Travel / Accommodation / Expenses: Pfizer. A. Hollebecque: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Janssen Cilag; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi. C. Massard: Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): BMS; Research grant / Funding (self): Boehringer Ingelheim; Research grant / Funding (self): Janssen Cilag; Research grant / Funding (self): Merck, Novartis; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche; Research grant / Funding (self): Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: BeiGene; Advisory / Consultancy: BMS; Advisory / Consultancy: Celgene; Advisory / Consultancy: Debiopharm; Advisory / Consultancy: Genentech; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly. B. Besse: Research grant / Funding (self): Abbvie; Research grant / Funding (self): Amgen; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Biogen; Research grant / Funding (self): Blueprint Medicines; Research grant / Funding (self): BMS; Research grant / Funding (self): Celgene; Research grant / Funding (self): Eli Lilly; Research grant / Funding (self): GSK; Research grant / Funding (self): Ignyta; Research grant / Funding (self): IPSEN; Research grant / Funding (self): Merck KGaA; Research grant / Funding (self): MSD; Research grant / Funding (self): Nektar; Research grant / Funding (self): Onxeo; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Pharma Mar; Research grant / Funding (self): Sanofi; Research grant / Funding (self): Spectrum Pharmaceuticals; Research grant / Funding (self): Takeda. J. Soria: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Astex; Advisory / Consultancy: Clovis; Advisory / Consultancy: GSK; Advisory / Consultancy: GamaMabs; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Mission Therapeutics; Advisory / Consultancy: Merus; Advisory / Consultancy: Pfizer; Advisory / Consultancy: PharmaMar; Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Servier; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Takeda; Full / Part-time employment: AstraZeneca. S. Postel Vinay: Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): BMS; Research grant / Funding (self): Boehringer Ingelheim; Research grant / Funding (self): Janssen Cilag; Research grant / Funding (self): Merck; Research grant / Funding (self): Novartis; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche; Research grant / Funding (self): Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
4596 - A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis (MBM) (POLARIS)
Presenter: Michael Davies
Session: Poster Display session 3
Resources:
Abstract
1891 - Continuation of annual screening mammograms and breast-cancer mortality in women over 70
Presenter: Xabier Garcia De Albeniz
Session: Poster Display session 3
Resources:
Abstract
5587 - Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Presenter: Istvan Petak
Session: Poster Display session 3
Resources:
Abstract
4757 - Effectively using primary care givers in oncology care through capacity building, task sharing and techno-mentoring.
Presenter: Dinesh Pendharkar
Session: Poster Display session 3
Resources:
Abstract
4497 - A single institution review of capecitabine related acute admissions and cost analysis
Presenter: Gemma Dart
Session: Poster Display session 3
Resources:
Abstract
2187 - Health status of middle-aged and older cancer survivors in China: results from the China Health and Retirement Longitudinal Study (CHARLS)
Presenter: Jiarui Li
Session: Poster Display session 3
Resources:
Abstract
5101 - Crossed looks on lung cancer perception and knowledge from general public and physicians in France: results of a two-fold survey
Presenter: Céline Mascaux
Session: Poster Display session 3
Resources:
Abstract
4354 - Knowledge and perception of clinical trials (CTs) and attitude towards participation among Polish oncological patients - A pilot survey
Presenter: Artur Kotowski
Session: Poster Display session 3
Resources:
Abstract
3499 - Achieving best possible cancer treatment outcomes in care pathways through benchmarking; ABC-Benchmarking
Presenter: Anke Wind
Session: Poster Display session 3
Resources:
Abstract
2270 - Impact of 10-day Fulbright Specialist Program (FSP) and Project Pink Blue (PPB) Education Sessions on Medical Oncology knowledge among Doctors that treat cancer in Nigeria
Presenter: Mike Martin
Session: Poster Display session 3
Resources:
Abstract